-transparent.png){kind=logo}
Twenty renal allograft recipients were treated with antithymocyte globulin (ATGAM; ATG) for up to 16 weeks in addition to azathioprine and prednisone, while 20 controls received no ATG. The ATG group showed a lower incidence of first rejection episodes during the first month after transplantation, and also a better functional graft survival rate up to 2 years after transplantation. The results in this early ATG trial were better than those in subsequent trials which used 14-day treatment regimens. Longer treatment deserves another look.
Related Publications
W J Wechter, and
R M Morrell, and
J Bergan, and
J C Rosenberg, and
J Turcotte, and
J R Schultz
May 1978,
The Journal of surgical research,
W J Wechter, and
R M Morrell, and
J Bergan, and
J C Rosenberg, and
J Turcotte, and
J R Schultz
October 1979,
Transplantation,
W J Wechter, and
R M Morrell, and
J Bergan, and
J C Rosenberg, and
J Turcotte, and
J R Schultz
October 1979,
Transplantation,
W J Wechter, and
R M Morrell, and
J Bergan, and
J C Rosenberg, and
J Turcotte, and
J R Schultz
November 1983,
Transplantation,
W J Wechter, and
R M Morrell, and
J Bergan, and
J C Rosenberg, and
J Turcotte, and
J R Schultz
December 1984,
Transplantation proceedings,
W J Wechter, and
R M Morrell, and
J Bergan, and
J C Rosenberg, and
J Turcotte, and
J R Schultz
January 1987,
The Journal of heart transplantation,
W J Wechter, and
R M Morrell, and
J Bergan, and
J C Rosenberg, and
J Turcotte, and
J R Schultz
August 1976,
Surgery,
W J Wechter, and
R M Morrell, and
J Bergan, and
J C Rosenberg, and
J Turcotte, and
J R Schultz
December 1980,
Transplantation,
W J Wechter, and
R M Morrell, and
J Bergan, and
J C Rosenberg, and
J Turcotte, and
J R Schultz
February 1981,
Transplantation,
W J Wechter, and
R M Morrell, and
J Bergan, and
J C Rosenberg, and
J Turcotte, and
J R Schultz
June 2009,
Journal of the American Society of Nephrology : JASN,
